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HIV-1 Vpr-binding protein (VprBP) has been implicated in the regulation of both DNA replication and cell cycle progression,
but its precise role remains unclear. Here we report that VprBP regulates the p53-induced transcription and apoptotic pathway.
VprBP is recruited to p53-responsive promoters and suppresses p53 transactivation in the absence of stress stimuli. To maintain
target promoters in an inactive state, VprBP stably binds to nucleosomes by recognizing unacetylated H3 tails. Promoter-
localized deacetylation of H3 tails is a prerequisite for VprBP to tether and act as a bona fide inhibitor at p53 target genes. VprBP
knockdown leads to activation of p53 target genes and causes an increase in DNA damage-induced apoptosis. Moreover, phos-
phorylation of VprBP at serine 895 impairs the ability of VprBP to bind H3 tails and to repress p53 transactivation. Our results
thus reveal a new role for VprBP in regulation of the p53 signaling pathway, as well as molecular mechanisms of cancer develop-
ment related to VprBP misregulation.
VprBP was first identified as a protein that can interact withHIV-1 viral protein R by coimmunoprecipitation assays (37).
VprBP is a 1,507-amino-acid protein that contains conserved do-
mains, including YXXY repeats, the Lis homology motif, and
WD40 repeats. Despite the lack of molecular characterization of
VprBP, recent studies suggest that VprBP can specifically associate
with DDB1 to act as a substrate recognition subunit of the CUL4-
DDB1 ubiquitin E3 ligase complex (12, 20, 26, 33, 36, 38).
Through binding to Vpr, VprBP allows Vpr to modulate the in-
trinsic catalytic activity of the CUL4-DDB1 complex, which in
turn leads to the induction of G2 phase cell cycle arrest in the
virus-infected cells. The direct interaction of tumor suppressor
Merlin with VprBP is shown to be an integral part of the mecha-
nism by which Merlin inhibits CUL4-DDB1 ubiquitin E3 ligase to
suppress tumorigenesis (22). Furthermore, the observation that
VprBP-depleted cells activate DNA damage checkpoints and in-
crease the cellular level of CDK inhibitor p21 suggests that VprBP
is involved in the control of cell cycle arrest and apoptosis (11).
p53 is an important tumor suppressor which induces either cell
cycle arrest or apoptosis in response to DNA damage (27, 30, 34).
p53 regulates these processes mainly by acting as a sequence-
specific DNA binding factor that regulates transcription of a num-
ber of target genes. p53 regulates the transcription reaction, to a
large extent, at the level of chromatin, which establishes a physical
barrier for the binding of transcription factors to the promoter
region of a target gene. The most dynamic parts of chromatin are
amino-terminal domains (called histone “tails”) of core histones,
which protrude from the DNA. The major contributions of indi-
vidual histone tails in gene transcription are made through their
posttranslational modifications (3, 18, 21, 29, 35). Among various
modifications, histone acetylation has been implicated as a critical
mark for activation of p53 target genes (1, 5, 7, 10, 13). While
acetylation of all four histone tails has been linked to active tran-
scription, there is an emerging body of evidence to support that
acetylation of H3 and H4 tails is particularly important for tran-
scriptional activation of p53 target genes (1, 5, 7, 10, 13, 23). When
cells are exposed to stress conditions, p53 recruits histone acetyl-
transferases (HATs) to establish distinct histone acetylation at its
target gene promoters, which will in turn allow the transcriptional
machinery to initiate the high level of transcription. Because his-
tone acetylation is actively regulated by a competitive action of
HAT and histone deacetylase (HDAC) (15, 25, 31, 32), the dereg-
ulation of this chromatin-remodeling process can lead to aberrant
repression of p53 target genes. Given this reversible nature of his-
tone acetylation, cells need to employ additional factors that can
recognize and lock in a distinct (de)acetylation status of promoter
nucleosomes. In relation to the present study, the cellular deple-
tion of VprBP leads to the increased expression of the p53 target
gene p21 (11). These results raise questions about whether VprBP
is able to downregulate p53-mediated transcription and, if so, how
this would affect cellular responses to DNA damage.
In this study, we demonstrate that VprBP is recruited to pro-
moters by p53 and attenuates p53-dependent transcription. This
occurs through VprBP interaction with histone H3 tails and inhi-
bition of their acetylation at promoter regions. HDAC1-mediated
deacetylation of H3 tails contributes to the stable localization of
VprBP at p53 target promoters. VprBP is overexpressed in three
types of cancer cell lines, and RNA interference (RNAi) against
VprBP augments DNA damage-induced apoptotic cell death. Fur-
thermore, VprBP phosphorylation by DNA-activated protein ki-
nase (DNA-PK) inhibits its interaction with promoter nucleo-
somes and reactivates p53 target genes. Together, these results
reveal a hitherto-unknown role of VprBP in repressing p53-
dependent transcription and a distinct regulatory mechanism
governing VprBP function under stress conditions.
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MATERIALS AND METHODS
Cell culture and constructs. U2OS, 293T, LD611, and MCF7 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS). MCF10-2A cells were grown in a 1:1
mixture of DMEM and DMEM-F12 supplemented with 20 ng/ml epider-
mal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500
ng/ml hydrocortisone, and 5% horse serum. Urotsa cells were grown in
DMEM (low glucose) containing 10% FBS. MLC cells were grown in T
medium containing 10% FBS. LNCaP cells were grown in RPMI-1640
with 10% FBS. Wild-type and VprBPflox/ MEF cells were propagated in
DMEM supplemented with 10% FBS as previously described (26).
The p53ML601-14 plasmid was constructed as recently described
(17). To generate the glutathione S-transferase (GST)-p53 and GST-
HDAC1 constructs, the corresponding cDNAs were amplified by PCR
and inserted into the BamHI and EcoRI sites of pGEX-4T1. Bacterial
expression constructs of VprBP deletion mutants were generated by PCR
tagging of the corresponding cDNA and subcloning them into the pET-
15b or pET-11d vector in frame with 5= hexa-His or Flag sequences, re-
spectively. For mammalian expression of HDAC1 and p53, the corre-
sponding cDNAs were amplified by PCR and ligated into the correct
reading frame of pIRES containing the 5= Flag coding sequence or
pCDNA3.1/His. Further details of plasmid construction are available
upon request. Expression vectors for core histones, Flag-p53, and GST-
histone tails were as described previously (1, 2, 24).
Antibodies. Rabbit polyclonal antibody against S895-phosphorylated
VprBP was generated by using the VTAAApSPVSLPRKKC peptide as an
immunogen. Bleeds were passed three times through a nonphospho pep-
tide column to remove antibody that recognizes the peptide without
phosphorylation. The final flowthrough was loaded on a phosphopeptide
column, which was washed three times with 0.1 M Tris buffer (pH 8.0).
Bound antibody was eluted with 0.1 M glycine (pH 2.5) and neutralized
with 1 M Tris buffer. For the dot blot assay, serial dilutions of unmodified
or phosphorylated peptides were spotted on a polyvinylidene difluoride
(PVDF) membrane and blotted with the phospho-S895 antibody. For
peptide competition assays, the antibody was preincubated with unmod-
ified or phosphorylated peptides at room temperature for 60 min before
immunoblotting. Other antibodies used in this study are as follows: anti-
H3, anti-acetyl H3, anti-H4, anti-acetyl H4, and anti-Myc antibodies (Ab-
cam); anti-VprBP antibody (Proteintech Group); anti-HDAC1 antibody
(Active Motif); anti-His antibody (Novagen); anti-p53 antibody (Santa
Cruz Biotech); and anti-Flag antibody (Sigma).
Preparation of recombinant proteins and H3 tail peptides. Recom-
binant histones were expressed in Escherichia coli Rosetta 2(DE3)pLysS
cells (Novagen) and purified as described previously (1, 9). GST-fused
proteins were expressed in E. coli Rosetta 2(DE3)pLysS cells and purified
on glutathione-Sepharose 4B beads as described previously (16). Bacteri-
ally expressed His-tagged and Flag-tagged VprBP fragments were initially
purified with Ni-nitrilotriacetic acid (NTA) and M2 agarose, respectively,
and further purified with Q Sepharose and SP-HP columns according to
standard procedures. VprBP and p300 proteins were expressed as His-
tagged proteins in insect (Sf9) cells using a baculovirus vector and purified
by Ni-NTA affinity chromatography. The peptides corresponding to the
N-terminal tail of H3 (amino acids 1 to 28) were synthesized by Genemed
Synthesis Inc. (South San Francisco, CA) by solid-phase Fmoc/tBu chem-
istry using an automated peptide synthesizer. The synthesized peptides
were purified by reverse-phase high-performance liquid chromatography
(RP-HPLC) on a Zorbax SB300 C8 column (9.4 mm by 25 cm) using a
water (0.1% trifluoroacetic acid [TFA])-to-acetonitrile (0.1% TFA) gra-
dient, and peptide purity was confirmed using electrospray ionization
mass spectrometry (ES-MS) and amino acid analysis.
Reconstitution of nucleosome arrays and mononucleosomes. For
nucleosome array reconstitution, the p53ML601-14 plasmid was digested
with EcoRI and HindIII, and the 3.4-kb p53ML-601 array DNA fragment
was gel purified. For mononucleosome reconstitution, the 207-bp p53RE
DNA fragment containing p53 response elements was PCR amplified
from the p53ML601-14 plasmid using a pair of 5= biotinylated primers.
The nucleosome array and mononucleosome were reconstituted by salt
gradient dialysis and purified by sedimentation in a 5 to 30% (vol/vol)
glycerol gradient (14). Micrococcal nuclease (Sigma) digestion of nucleo-
some arrays (2 g) was performed as described previously (1). Reconsti-
tuted nucleosome arrays and mononucleosomes were analyzed on a 1%
agarose nucleoprotein gel stained with ethidium bromide.
In vitro transcription and modification assays. In vitro transcrip-
tion assays were as described previously (16) except that 100 ng of
p53ML-601 nucleosome arrays or an equimolar amount of DNA tem-
plates was used for each reaction. VprBP (25 or 50 ng) was added
before, after, or together with p300 (20 ng) and acetyl-coenzyme A
(Ac-CoA) (10 M). Transcription assays using DNA-PK were as de-
scribed above, but VprBP was preincubated with DNA-PK (50 ng) and
ATP (10 mM) for 60 min. For the chromatin HAT assay, p53ML-601
nucleosome arrays (200 ng) were preincubated with p53 (15 ng) for 20
min and then with p300 (20 ng), Ac-CoA (10 M), and/or VprBP (25
or 50 ng) for another 60 min. HAT reactions were analyzed by Western
blotting with H3, acetyl-H3, H4, and acetyl-H4 antibodies. To identify
posttranslational modifications of VprBP, in vitro modification assays
were performed using a panel of kinases (DNA-PK, ATM, and ATR),
acetyltransferases (p300, Tip60, and PCAF), and methyltransferases
(SET7, G9a, and PRMT1), supplemented with [-32P]ATP, [3H]Ac-
CoA, and S-[3H]adenosylmethionine ([3H]SAM). The reactions were
subjected to SDS-PAGE and autoradiography. To determine VprBP
phosphorylation sites, DNA-PK phosphorylation reactions were re-
solved by 15% SDS-PAGE and visualized by Coomassie blue staining.
The band corresponding to the VprBP 751–909 fragment was excised
from the gel and subjected to liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis.
H3 tail- and nucleosome-binding assays. To analyze the VprBP-tail
interaction in vitro, GST-histone tails (2 g) were immobilized on
glutathione-Sepharose beads and incubated with full-length or truncated
VprBP (2 g) for 16 h at 4°C in 750 l of binding buffer (25 mM Tris-HCl,
pH 7.8, 0.2 mM EDTA, 20% glycerol, 200 mM KCl, 0.1% Nonidet P-40).
The beads were washed three times with binding buffer, and bound pro-
teins were subjected to SDS-PAGE followed by immunoblotting. For H3
tail peptide binding experiments, His-VprBP (2 g) was coupled with
Ni-NTA agarose beads and incubated with unmodified or acetylated H3
peptides (2 g) for 16 h at 4°C in the binding buffer. After washing the
beads three times, tail peptides bound to the VprBP protein were resolved
by 4 to 20% SDS-PAGE and analyzed by silver staining. To study the effect
of phosphorylation on VprBP-H3 tail interaction, the wild-type or S895-
mutated version of Flag-VprBP 751–1507 was phosphorylated by
DNA-PK and incubated with immobilized GST-H3 tails. After extensive
washing with washing buffer (25 mM Tris-HCl, pH 7.8, 0.2 mM EDTA,
20% glycerol, 300 mM KCl, 0.1% Nonidet P-40), the bound VprBP pro-
tein was subjected to SDS-PAGE and detected by Western blotting using
anti-Flag antibody. For nucleosome binding assays, 2 g DNA equivalents
of mononucleosomes were preacetylated by p53 (150 ng) and p300
(200 ng) supplemented with Ac-CoA (10 M) and immobilized on
streptavidin-agarose (Novagen). After the beads were washed to remove
p53, p300, and Ac-CoA, His-tagged VprBP was added to mononucleo-
somes and incubated in 500 l of binding buffer at 4°C for 16 h. The beads
were washed three times with binding buffer, and nucleosome-bound
VprBP was detected by Western blotting using the anti-His antibody.
Protein-protein interaction. For GST pulldown assays, His-tagged
VprBP (2 g) was incubated with GST-p53 (2 g) or GST-HDAC1 (2 g)
immobilized on glutathione-Sepharose beads in 750 l of binding buffer
for 16 h at 4°C with gentle rotation. After beads were washed three times
with binding buffer, bound VprBP was resolved by 8% SDS-PAGE and
detected by Western blot analysis using anti-His antibody. Similar pull-
down assays were carried out using Flag-p53 (2 g) and GST-HDAC1 (2
g), and p53 binding was determined by Western blotting with anti-Flag
antibody. For in vivo interaction studies, 293T cells were transiently trans-
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fected with expression vectors encoding Myc-VprBP, Flag-p53, Flag-
HDAC1, and His-HDAC1. Two days after transfection, cells were solubi-
lized, and the cleared lysates were subjected to immunoprecipitation with
anti-Flag antibody. The bound proteins were eluted by boiling in SDS
sample buffer and analyzed by Western blot analysis. For coimmunopre-
cipitation of endogenous proteins, 293T cell lysates (1 mg) were immu-
noprecipitated using anti-p53 or anti-HDAC1 antibody and immuno-
blotted with anti-VprBP, anti-HDAC1, or anti-p53 antibody.
qRT-PCR, immunofluorescence, and cell viability and apoptosis as-
says. For qRT-PCR analysis of p53 target gene expression, total RNA was
isolated using the RNeasy minikit (Qiagen) according to the manufactur-
er’s instructions. Quantitative reverse transcription-PCR (qRT-PCR)was
performed using the IQ SYBR green Supermix (Bio-Rad) and the IQ5
real-time cycler (Bio-Rad). Assay results were normalized to -actin
mRNA levels. All reactions were run in triplicate, and data presented are
the averages of data from three individual experiments. Sequences of the
primers used for qRT-PCR are available upon request. Immunofluores-
cence was essentially as described previously (16).
The cytotoxicity of etoposide treatment was estimated by 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay
according to the standard protocol. Briefly, wild-type and VprBPflox/
mouse embryonic fibroblast (MEF) cells were first transfected with Cre
recombinase peptides to delete the VprBP gene (28) and treated with or
without etoposide (100 M). After cells were washed with phosphate-
buffered saline (PBS), 1 ml of MTT (0.5 mg/ml) was added to cells for 3 h
at 37°C. The MTT formazan precipitate was dissolved with 1 ml of MTT
solvent, and cellular proliferation was determined from the conversion of
MTT to formazan using a microplate reader, model 680 (Bio-Rad) at a
wavelength of 570 nm with background subtraction at 650 nm. For the
apoptosis assay, LD611, LNCaP, and MCF7 cells were cultured in
100-mm plates and treated with or without etoposide (100 M) for 24 h.
After the treatment, the cells were harvested with trypsin-EDTA, resus-
pended in the binding buffer, and incubated with fluorescein isothiocya-
nate (FITC)-conjugated annexin V and propidium iodide (FITC annexin
V apoptosis detection kit I; BD Pharmingen), according to the manufac-
turer’s protocol. The numbers of apoptotic cells were monitored with
flow cytometry.
ChIP, ChIP and re-ChIP, and RNA interference. Chromatin immu-
noprecipitation (ChIP) assays with U2OS cells, either treated or not
treated with etoposide, were performed using the ChIP assay kit from
Upstate/Millipore according to the manufacturer’s protocol and as re-
cently described (16). Antibodies specific to VprBP, H3, acetyl-H3, p53,
and HDAC1 were used for immunoprecipitation. ChIP assays with U2OS
cells expressing Myc-tagged VprBP were performed 2 days after transfec-
tion with or without 8 h of etoposide treatment using anti-Myc antibody.
Sequences of the primers used for quantitative real-time PCR (qPCR) are
available upon request. All samples were run in triplicate, and results were
averaged. The positions of the PCR primers within the promoter regions
are shown in Fig. 5. For re-ChIP assays, complexes from the initial ChIP
using anti-p53 antibody were eluted with 100 l of 10 mM DTT at 37°C
for 30 min and diluted 1:20 in immunoprecipitation (IP) dilution buffer.
The eluates were reimmnunoprecipitated with control IgG or anti-VprBP
antibody.
For short hairpin RNA (shRNA)-based knockdown experiments with
U2OS cells, DNA oligonucleotides encoding shRNAs specific for VprBP
mRNA (5=-AATCACAGAGTATCTTAGA-3=), p53 mRNA (5=-GACTCC
AGTGGTAATCTAC-3=), and HDAC1 mRNA (5=-GCAGATGCAGAGA
TTCAAC-3=) were subcloned into the H1 promoter-driven vector
pSUPER.puro (OligoEngine). U2OS cells were transfected with the indi-
cated shRNA expression constructs and then subjected to ChIP analysis.
For gene knockdown experiments with LD611, LNCaP, and MCF7 cells,
21 nucleotide small interfering RNA (siRNA) duplexes with 3= dTdT
overhangs corresponding to VprBP mRNA (5=-UCACAGAGUAUCUUA
GAGA-3=) were synthesized by the DNA Core Facility at the University of
Southern California. Cells were transfected with siRNA oligonucleotides
(60 M) or negative-control siRNA (Ambion). At 48 h posttransfection,
cells were treated with dimethyl sulfoxide (DMSO) or etoposide (100
M) and subjected to qRT-PCR analysis.
RESULTS
VprBP regulates cell viability and p53 target gene expression. To
examine the functional involvement of VprBP in regulating p53
responses more precisely, we employed conditional VprBPflox/
MEF cells that allow switching VprBP expression on and off under
the control of Cre recombinase. As determined by Western blot
analysis, the transfection of wild-type MEF cells with cell-permeating
TAT-Cre recombinase did not affect VprBP expression (Fig. 1A,
lanes 1 and 3), but the same treatment of VprBPflox/ MEF cells with
the TAT-Cre recombinase resulted in ablation of VprBP expression
(lanes 2 and 4). We first measured the level of transcription of two p53
target genes, the p21 and Noxa genes, by quantitative reverse
transcription-PCR (qRT-PCR). As summarized in Fig. 1B, a distinct
increase in DNA-damage-induced transcription of the p21 and Noxa
genes was detectable after Cre-mediated deletion of the VprBP gene
in VprBPflox/ MEF cells but not in wild-type MEF cells.
To address whether the observed contribution of VprBP to p53
target genes is accompanied by an alteration in cell proliferation,
we next investigated its effect on cell viability. MTT assays of wild-
FIG 1 Effects of VprBP knockout on cell viability. (A) Conditional knockout of VprBP expression. Wild type and VprBPflox/ MEF cells were treated with Cre
recombinase peptides for 72 h, and VprBP deletion was confirmed by Western blot analysis using anti-VprBP antibody. (B) Transcriptional activation of the p21
and Noxa genes by VprBP knockout. Wild-type and VprBPflox/ MEF cells were treated with etoposide (100 M) for 24 h, and total RNA was isolated and
analyzed by qRT-PCR analysis. Averages and standard deviations of data from three independent experiments are shown. (C) Decreased cell viability by VprBP
knockout. Wild-type and VprBPflox/ MEF cells were treated with etoposide as for panel B. Cell viability was measured by analysis of MTT conversion. All
reactions were carried out in triplicate.
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type and VprBPflox/ MEF cells showed no significant difference
in cell viability upon treatment with the DNA-damaging agent
etoposide without Tat-Cre recombinase transfection (Fig. 1C,
Cre). In contrast, similar assays revealed that cell viability upon
etoposide treatment was markedly reduced by Cre recombinase-
mediated deletion of the VprBP gene in VprBPflox/ MEFs (Fig.
1C, Cre). These observations imply that VprBP can contribute
to the regulation of p53 transactivation and cell survival.
VprBP represses p53-mediated transcription from chroma-
tin. To further define the functional role of VprBP, we prepared
recombinant VprBP (Fig. 2A) and examined its effects on p53-
mediated transcription using a cell-free assay system. For recon-
stitution of linear nucleosome arrays, we employed a p53ML-601
array template containing five copies of the p53 response element
and the adenovirus major late core promoter and, on both sides,
seven direct repeats of the 601 nucleosome positioning sequence
(17). Unmodified nucleosomal arrays were assembled from re-
combinant histone octamers and p53ML-601 array DNA by salt
gradient dialysis. After confirming the successful reconstitution
by partial micrococcal nuclease digestion (data not shown), tran-
scription assays were carried out with p53 and p300 HAT as sum-
marized in Fig. 2B. Transcription from p53ML-601 nucleosome
arrays was completely dependent upon p53, p300 HAT, and Ac-
CoA, whereas transcription from the p53ML-601 DNA template
showed a dependence only on the activator p53 (Fig. 2C, lanes 1 to
3). When the effect of VprBP was examined, we found that addi-
tion of VprBP prior to p300 significantly decreased the level of
transcription from nucleosome array templates (Nuc array, lanes
4 and 5). However, no detectable change in transcription was ob-
served upon simultaneous addition of VprBP and p300 or sequen-
tial addition of VprBP after p300 (Nuc array, lanes 10, 11, 16, and
17). A similar transcription analysis with histone-free DNA tem-
plates also failed to show any effect of VprBP (Fig. 2C, DNA).
Addition of VprBP to transcription reactions carried out with two
Gal4-based activators (i.e., Gal4-VP16 and Gal4-CTF) showed no
obvious changes in transcription (data not shown). These results
confirm that the repressive effect of VprBP on chromatin tran-
scription is highly dependent on p53.
Because the primary role of acetylated H3 and H4 tails has been
well illustrated in p53-mediated transcription (1, 6, 10, 13), a pos-
sible interpretation of these results is that VprBP could repress
p300-mediated acetylation of H3 and H4 at the promoter region.
This possibility was investigated by checking whether VprBP is
also repressive for acetylation of H3 and H4 within reconstituted
nucleosome arrays. Western blots of HAT reactions confirmed
that p300-mediated histone acetylation in the context of nucleo-
some arrays is completely dependent on p53, which is known to
recruit p300 for promoter-targeted acetylation (Fig. 2D, lanes 1 to
3). In parallel experiments with VprBP, we observed a significant
inhibition of H3 acetylation but not H4 acetylation by addition of
VprBP prior to p300 (lanes 4 and 5). As expected from transcrip-
tion assays, there was no apparent repression of H3 acetylation,
when VprBP was added after or simultaneously with p300 (lanes
10, 11, 16, and 17). When the same concentration of the heat-
inactivated VprBP was tested for transcription and HAT assays, no
inhibitory effect was detected (Fig. 2C and D, lanes 6, 12, and 18),
further supporting specificity of VprBP-induced repression of H3
acetylation and chromatin transcription.
VprBP binds to unmodified H3 tail in the context of the
nucleosome. A potential mechanism underlying the inhibitory
action of VprBP in transcription is that VprBP interacts with his-
tone tails, especially H3 tails, to repress their acetylation. To test
this possibility, we examined the interaction of His-VprBP with
GST-histone tail fusion proteins prebound to glutathione-
Sepharose beads. After extensive washing of the beads, VprBP
binding was determined by Western blotting with anti-His anti-
body. As shown in Fig. 2E, we found that VprBP binding was
highly selective for H3 tail. Because VprBP lost its repressive ac-
tivity when nucleosomal arrays were preacetylated by p300 (Fig.
2C), we further analyzed the effect of tail acetylation on H3 tail-
VprBP interaction using synthetic tail peptides. When incubated
with immobilized His-VprBP, unmodified H3 tail peptides
showed a distinct interaction with VprBP, as confirmed by silver
staining after SDS-PAGE of the reactions (Fig. 2F, lane 4). In con-
trast, a parallel experiment with H3 tail peptides bearing lysine
acetylations at K9, K14, K18, and K23 showed no detectable inter-
action of VprBP (lane 5). Additionally, similar binding experi-
ments with mononucleosomes reconstituted on a 207-bp p53RE
DNA fragment showed VprBP binding both to nucleosomes con-
taining wild-type H3 and to nucleosomes containing lysine-
mutated H3 (Fig. 2G, lanes 1 and 3). Notably, however, the
observed VprBP-nucleosome interaction was inhibited by p300-
mediated H3 acetylation, as reflected by an apparent decrease in
binding of VprBP to wild-type H3 nucleosome but not to H3-
mutated nucleosome (Fig. 2G, lane 2 versus lane 4).
The LisH motif of VprBP is required for its repressive action.
VprBP contains an evolutionally conserved Lis homology (LisH)
motif in the central region and several WD40 repeats in the
carboxyl-terminal region (Fig. 3A). Since these motifs are often
critical for known functions of full-length proteins, we were inter-
ested in determining which part of VprBP is required for its re-
pressive action. To this end, three different VprBP fragments were
prepared from bacteria (Fig. 3B) and tested in transcription and
HAT assays. The N-terminal fragment (residues 1 to 750) and
C-terminal fragment containing WD40 repeats (residues 910 to
1507) showed no detectable change in p53-dependent, p300-
mediated transcription of nucleosome arrays (Fig. 3C, Nuc array,
lanes 4, 5, 10, and 11). In striking contrast, the fragment carrying
both the C-terminal region and the central region containing the
LisH motif (residues 751 to 1507) repressed the nucleosome array
transcription to a level comparable to that observed with full-
length VprBP (Nuc array, lanes 7 and 8). As expected, transcrip-
tion from histone-free DNA was not altered by these VprBP frag-
ments in all cases (Fig. 3C, DNA). In HAT assays with nucleosome
arrays, we also observed a significant inhibition of p300-mediated
acetylation of H3 by residues 751 to 1507 containing the LisH
motif but not by residues 1 to 750 or 910 to 1507 (Fig. 3D, AcH3).
Because VprBP binds to unmodified H3 tails to act as a tran-
scription repressor (Fig. 2E and F), the above results argue that the
LisH motif in the central region might be important for the inter-
action between VprBP and H3 tails. In fact, GST pulldown assays
with the deletion mutants of VprBP revealed that only residues
751 to 1507 can interact with H3 tails (Fig. 3E, lane 3), indicating
that the LisH motif is responsible for the interaction of VprBP
with H3 tails. Similar binding experiments with unmodified or
acetylated H3 tail peptides also showed that, in contrast to
N-terminal (residues 1 to 750) and C-terminal (residues 910 to
1507) fragments, the fragment (residues 751 to 1507) carrying
both central and C-terminal regions can bind to these peptides
(Fig. 3F, lanes 4 and 5). Importantly, however, the fragment
Kim et al.
786 mcb.asm.org Molecular and Cellular Biology
FIG 2 VprBP-mediated repression of chromatin transcription and H3 acetylation. (A) Analysis of purified VprBP by 8% SDS-PAGE and Coomassie blue
staining. (B) Outline of chromatin HAT and transcription assays. Abbreviations: AcCoA, acetyl-CoA; PIC, preinitiation complex; NTPs, nucleotide triphos-
phates. (C) Repressive effect of VprBP on chromatin transcription. p53ML-601 nucleosome array or histone-free p53ML-601 DNA was transcribed in the
presence of p53, p300, Ac-CoA, and/or VprBP as summarized for panel B. Prior to transcription, p300 and VprBP were added together or sequentially as
indicated. Heat-inactivated VprBP was used in control transcription reactions, marked by an asterisk (lanes 6, 12, and 18). Data were quantitated by using a
phosphorimager, and the results shown are representative of three independent experiments. (D) Repressive effect of VprBP on H3 acetylation. The p53ML-601
nucleosome array was incubated with p53, p300, Ac-CoA, and/or VprBP as summarized in panel B. Acetylation of nucleosome arrays was detected by Western
blotting with anti-acetyl H3 and H4 antibodies (AcH3 and AcH4). Western blot analyses of H3 and H4 confirmed equal loading of histones (H3 and H4). (E)
Selective interaction of VprBP with H3 N-terminal tail. His-tagged VprBP was tested for binding to GST (lane 2) or GST-histone tail fusion (lanes 3 to 6) proteins.
VprBP binding to histone tails was determined by Western blot analysis using anti-His antibody. Lane 1 represents 10% of VprBP used in the binding reactions.
(F) Selective interaction of VprBP with unmodified H3 tail. Unmodified (H3) and acetylated (AcH3) H3 peptides (amino acids 1 to 28) were synthesized and
incubated with His-tagged VprBP immobilized on Ni-NTA agarose beads. After extensive washing, bound H3 peptides were resolved in a 4 to 20% SDS-PAGE
gel and silver stained. Input lanes 1 and 2 represent 10% of tail peptides used in the binding reactions. (G) Preferential binding of VprBP to unmodified
nucleosome. Nucleosomes containing wild-type or mutant H3 were reconstituted on biotinylated 207-bp p53 RE and incubated with p300, p53, and/or Ac-CoA.
After reconstituted nucleosomes and free DNA were immobilized on streptavidin-agarose beads, the interaction assays were performed with VprBP. The
presence of VprBP in the beads was analyzed by Western blotting with anti-His antibody.
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showed a marked preference for unmodified H3 peptides over
acetylated H3 peptides (compare the asterisk-marked bands).
VprBP downregulates p53 target genes by modulating his-
tone acetylation. To assess the in vivo relevance of our in vitro
results, we determined whether VprBP can antagonize H3 acety-
lation at p53 target promoters by RNAi-complemented ChIP as-
says. Based on recent indications that HDAC1 acts as a key repres-
sor of p53 transactivation by blocking histone acetylation (8, 19),
we also examined the promoter localization of HDAC1 and its
relationship with VprBP occupancy at the promoter. As first con-
firmed by Western blotting, the transfection of U2OS cells with
shRNAs against VprBP, p53, and HDAC1 efficiently depleted
their respective target proteins (Fig. 4A). Interestingly, in contrast
with a recent report showing that the expression level of p53 is
relatively high in VprBP-depleted cells (11), our data demon-
strated no detectable alteration in the p53 protein level after
VprBP knockdown. In checking the transcription of p53-
responsive genes, such as p21, Gadd45, Bax, Casp8, and Noxa, by
qRT-PCR, we found that RNAi depletion of p53 led to a severe
reduction in transcription after DNA damage, indicating that p53
is the major regulator of these genes (Fig. 4B, Eto). In contrast,
upon depletion of VprBP or HDAC1, there was a significant en-
hancement in DNA-damage-induced transcription of the target
genes to a comparable extent. Similar experiments without DNA
damage showed, although to a much lower extent, a detectable
increase in transcription after depletion of VprBP or HDAC1 (Fig.
4B, ). The fact that the individual depletion of VprBP and
HDAC1 did not cause any changes in non-p53 target genes, the
Ctsd and Gapdh genes, further supports that VprBP and HDAC1
are required to maintain the repressed state of p53 target genes.
When ChIP experiments were performed with VprBP-
depleted U2OS cells under normal conditions, we detected a dra-
matic decrease in HDAC1 occupancy and a concomitant accumu-
lation of acetylated H3, but a minimal change in the level of p53, at
the p21 promoter region (Fig. 5A, top panel). In ChIP experi-
ments using p53-depleted cells, a significant reduction in H3 acet-
ylation and a near-complete loss of VprBP were evident (middle
panel). This observation strongly suggests that the initial recruit-
ment of VprBP and HDAC1 to the p21 promoter is mediated by
p53. One anomaly in this result is that the dissociation of HDAC1
from the p21 promoter coincides with the reduction of H3 acety-
lation (middle panel, AcH3 and HDAC1). This may be due to the
failure of p53-mediated recruitment of a HAT, which would ini-
tially acetylate H3 at the promoter. Also consistent with our results
FIG 3 Requirement of the LisH motif for VprBP action. (A) Schematic illustration of VprBP deletion mutants. Numbers indicate amino acid residues. The Lis
homology motif (LisH) and WD40 repeat motif (WD40) are indicated. (B) Preparation of VprBP deletion mutants. His-tagged or Flag-tagged VprBP proteins
were prepared as described in Materials and Methods and analyzed on an 8% SDS-PAGE gel stained with Coomassie blue. Lane 1, amino acids 1 to 750; lane 2,
amino acids 751 to 1507; lane 3, amino acids 910 to 1507. (C) Differential effects of VprBP deletion mutants on chromatin transcription. Transcription reactions
were carried out essentially as described for Fig. 2C, but mixtures contained VprBP deletion mutants which were added prior to p300. The asterisk indicates the
usage of heat-inactivated VprBP. (D) Differential effects of VprBP deletion mutants on H3 acetylation. HAT assays were carried out as described for Fig. 2D but
with the indicated VprBP deletion mutants. The heat-inactivated VprBP (marked with an asterisk) was also included. (E) Preferential binding of VprBP LisH
motif to H3 tail. GST pulldown assays were performed with GST-H3 tail and VprBP deletion mutants as indicated. Input (lane 1) represents 10% of mutant
proteins used in the binding experiments. (F) Preferential binding of VprBP LisH motif to unmodified H3 tail. Binding assays were performed using synthetic
H3 tail peptides as for Fig. 2F but with the indicated VprBP deletion mutants. The positions of unmodified and acetylated H3 tail peptides are indicated by single
and double asterisks, respectively. Lanes 1 and 2 show 10% of tail peptides used in the binding reactions.
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indicating a stable association of VprBP with unmodified H3 tail
(Fig. 2F and G), our ChIP assays after HDAC1 knockdown
showed a significant decrease in promoter localization of VprBP
but only little change in p53 occupancy (bottom panel). To ex-
plore the possible effect of VprBP on other p53 target genes, we
also carried out the same analysis on the Noxa gene. Consistent
with the results from the p21 gene, shRNA-mediated depletion of
VprBP at the Noxa promoter region was found to coincide with
dissociation of HDAC1 and an apparent increase in H3 acetyla-
tion (Fig. 5C). Depletion of p53 or HDAC1 also caused a reduc-
tion in immunoprecipitation of the promoter region using VprBP
antibody (middle and bottom panel), strongly supporting that
VprBP plays an inhibitory role in other p53 target genes as well.
To further investigate the repressive role of VprBP, we per-
formed ChIP analyses with U2OS cells that were either untreated
or treated with etoposide. Predictably, etoposide-induced DNA
damage resulted in an accumulation of p53 and a large increase in
H3 acetylation at the p21 promoter (Fig. 5B, p53 and AcH3, RE).
In correlation with the increased level of H3 acetylation, the re-
lease of VprBP from the promoter region was evident (VprBP,
RE). ChIP assays also showed that the dissociation of VprBP from
the promoter coincides with the decrease in HDAC1 occupancy at
the promoter region (HDAC1, RE), suggesting that HDAC1 bind-
ing and H3 deacetylation at the p21 promoter are dependent on
VprBP. In contrast, a minimal alteration in the levels of p53,
VprBP, H3 acetylation, and HDAC1 at the distal region was ob-
served upon DNA damage in all cases (Fig. 5B, Distal). To dem-
onstrate the coexistence of p53 and VprBP at the p21 promoter,
we also performed a ChIP–re-ChIP experiment. Expectedly, the
VprBP re-ChIP assay with anti-p53 immunoprecipitates resulted
in the precipitation of the p21 promoter DNA fragment (Fig. 6A,
p21 promoter), indicating that p53 and VprBP were bound to-
gether on the same p21 promoter. We repeated these experiments
with the Noxa gene; similar results were obtained from these par-
allel experiments (Fig. 5C and D and Fig. 6A, Noxa promoter).
These results support the idea that VprBP exerts its inhibitory
effects on transcription of other p53 target genes.
VprBP physically interacts with p53 and HDAC1. To deter-
mine if the recruitment and repressive action of VprBP at p53
target genes reflect its direct interaction with p53 and HDAC1, we
performed a series of binding studies. In initial binding experi-
ments, GST-p53 and GST-HDAC1 immobilized on Sepharose
beads were incubated with His-VprBP and Flag-p53, and the
bound proteins were detected by Western blotting after extensive
washing. As shown in Fig. 6B, His-VprBP was specifically precip-
itated from the reaction by both GST-p53 and GST-HDAC1
(lanes 3 and 6). In contrast, pulldown experiments in which GST-
HDAC1 was used under the same conditions failed to show any
detectable binding to Flag-p53 (lane 9). To validate these in vitro
results in vivo, extracts from 293T cells transiently expressing
Myc-VprBP, Flag-p53, and/or Flag- or His-HDAC1 were immu-
noprecipitated using anti-Flag antibody. Consistent with in vitro
binding data, our Western blot analysis showed a strong interac-
tion of VprBP with p53 and HDAC1 (Fig. 6C, lanes 3 and 6) but no
detectable interaction between p53 and HDAC1 (lane 9). The in-
teraction of VprBP with p53 and HDAC1 under physiological
conditions was further tested by Western blotting of anti-p53 and
anti-HDAC1 immunoprecipitates from extracts of 293T cells.
Again, both p53 and HDAC1 were coimmunoprecipitated with
VprBP, but HDAC1 failed to show coimmunoprecipitation of p53
(Fig. 6D).
Proapoptotic effect of VprBP knockdown in cancer cells.
Given demonstrated action of VprBP as a negative regulator of
p53, we next assessed the expression level of VprBP in three hu-
man cancer cell lines expressing wild-type p53: a bladder cancer
cell line (LD611), a prostate cancer cell line (LNCaP), and a breast
cancer cell line (MCF7). Based on our Western blotting of these
transformed cancer cells, a much higher level of VprBP expression
was evident than with nontransformed cells (Urotsa, MLC, and
MCF10-2A) (Fig. 7A, VprBP). Prostate (LNCaP) and breast
(MCF7) cancer cells also showed a higher level of HDAC1 than the
normal cells (HDAC1, lanes 4 and 6 versus lanes 3 and 5), arguing
for the functional connection between VprBP and HDAC1 as ob-
served at the p53 target genes.
FIG 4 Stimulatory effects of VprBP knockdown on p53 transcriptional targets. (A) Depletion of VprBP, p53, and HDAC1. U2OS cells were transfected with
VprBP shRNA (lane 2), p53 shRNA (lane 3), HDAC1 shRNA (lane 4), or control shRNA (lane 1), and Western blot analyses were performed using the indicated
antibodies. Actin was used as an internal control. (B) Relative effect of p53, VprBP, or HDAC1 knockdown on p53 target gene transcription. Cells depleted of
VprBP, p53, or HDAC1 were treated with 100 M etoposide for 12 h, and mRNA levels were analyzed by qRT-PCR. Averages and standard deviations of data
from three independent experiments are shown.
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In line with the repressive action of VprBP on p53 transcrip-
tion activity, a possible effect of VprBP depletion on expression of
the p21 and Noxa genes was examined in these cancer cell lines.
Because the shRNA-mediated knockdown of VprBP was not effi-
cient in these cell lines (data not shown), we employed synthetic
siRNA to achieve high-efficiency knockdown, as confirmed by
Western blot analysis (Fig. 7B, VprBP). When these VprBP-
depleted cells were treated with etoposide, the expression of the
p21 and Noxa genes was significantly stimulated, supporting
VprBP acting as a transcriptional repressor of p53 (Fig. 7C, Eto).
Although the p53 target genes exhibited very weak transcription
without etoposide treatment, a moderate enhancement in the tar-
get gene expression was also observed by VprBP depletion under
this uninduced condition (Fig. 7C, ). Of note, we did not see any
changes in the cellular level of p53 after VprBP depletion (Fig. 7B,
p53). Thus, it does not seem likely that the observed action of
VprBP on p53 target genes is related to VprBP-triggered degrada-
tion of p53.
Because p53-mediated transcription of the p21 and Noxa genes
represents the early stage of apoptosis, DNA damage-triggered
apoptosis that is compromised by VprBP overexpression in cancer
cells may be reactivated by VprBP depletion. To test this, we de-
pleted VprBP in the cancer cell lines and then subjected them to
apoptosis analysis. As summarized in Fig. 7D, VprBP depletion
resulted in an apparent increase in the proportion of apoptotic
cells, suggesting that endogenous VprBP plays an important role
in attenuating DNA damage-induced apoptosis.
VprBP is phosphorylated at serine 895 by DNA-PK. Knowing
that VprBP-H3 tail interaction is a key event in the inhibition of
p53-mediated transcription, we next sought to explore whether
the inhibitory effect of VprBP is reversible. Interestingly, although
the cellular level of p53 increased during the course of damage
FIG 5 Dynamics of promoter occupancy of VprBP, p53, and HDAC1. (A) VprBP depletion-promoted H3 acetylation at the p21 promoter. VprBP, p53, and
HDAC1 were depleted as for Fig. 4A, and ChIP assays of promoter and distal regions were performed using antibodies specifically recognizing VprBP, p53,
HDAC1, and acetyl H3. Input DNA and immunoprecipitated DNA were quantified by qPCR analyses using distal and proximal primer sets. The results are
shown as percentages of input, and the error bar indicates the means  SE. (B) DNA damage-induced dissociation of VprBP. U2OS cells were treated with or
without etoposide (100 M) for 8 h and then analyzed by ChIP analysis of p21 promoter as described for panel A. (C) VprBP depletion-promoted H3 acetylation
at the Noxa promoter. ChIP analyses were essentially as described for panel A but over the Noxa gene promoter. (D) DNA damage-induced dissociation of
VprBP. U2OS cells were either DMSO treated or etoposide (100 M) treated for 8 h and then analyzed by ChIP analysis of the Noxa promoter as described for
panel B.
FIG 6 Direct interaction of VprBP with p53 and HDAC1. (A) ChIP and re-ChIP assays were performed for the p21 or Noxa promoter in U2OS cells. Chromatin
fragments immunoprecipitated with anti-p53 antibody in the first ChIP were used as an input and were subjected to Re-ChIP analysis using control IgG or
anti-VprBP antibody. (B) VprBP interaction with p53 and HDAC1 in vitro. His-tagged VprBP or Flag-tagged p53 was incubated with GST or GST-fused p53 or
HDAC1, and bound proteins were analyzed by Western blotting using anti-His and anti-Flag antibodies as indicated. “Input” corresponds to 10% of the material
used in the binding reactions. (C) VprBP interaction with p53 and HDAC1 in vivo. 293T cells were transfected for 48 h with epitope-tagged forms of VprBP, p53,
and/or HDAC1. Whole-cell lysates were prepared and subjected to immunoprecipitation with anti-Flag antibody followed by Western blotting with indicated
antibodies (IP: -Flag). Cell extracts were also analyzed by Western blotting to confirm that equivalent amounts of proteins from each lysate were used for
immunoprecipitation (Total lysate). (D) Interaction of endogenous VprBP with p53 and HDAC1. Whole-cell extracts were prepared from 293T cells and
immunoprecipitated with anti-p53 (-DO1) or anti-HDAC1 (-HDAC1) antibody. The precipitates were analyzed by Western blotting with antibodies against
VprBP, HDAC1, and p53 as indicated. The asterisk in lane 3 indicates a nonspecific band containing IgG heavy chain.
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response, the level of VprBP remained fairly constant (Fig. 8A).
These results led us to speculate that VprBP may be postsyntheti-
cally modified upon DNA damage such that its interaction with
the H3 tail is hindered. To this end, we performed radioactive in
vitro modification assays with a panel of kinases (DNA-PK, ATM,
and ATR), acetyltransferases (p300, Tip60, and PCAF), and meth-
yltransferases (SET7, G9a, and PRMT1), all of which are known to
participate in the DNA damage response. SDS-PAGE and autora-
diography of the radioactively labeled modification reactions re-
vealed that VprBP can be modified by DNA-PK but not by other
factors (Fig. 8B). In order to delineate the location of the VprBP
phosphorylation sites, in vitro kinase assays were repeated with
different subregions of VprBP with DNA-PK. Our assays revealed
that the main phosphorylation site for DNA-PK is localized within
amino acids 751 to 909 of VprBP (Fig. 8C). As a more direct
approach toward localizing phosphorylation, mass spectrometric
sequencing was performed on the VprBP 751–909 fragment after
the phosphorylation reaction. Our analysis identified only a singly
phosphorylated peptide that could have arisen from phosphory-
lation of serine 895 (S895), which is in close proximity to the LisH
motif (Fig. 8D). Consistent with the mass spectrometric results,
S895-mutated VprBP is phosphorylated by DNA-PK at a much
lower level than the wild-type protein (Fig. 8E). To further inves-
tigate the role of VprBP phosphorylation, we raised and purified a
rabbit polyclonal antibody that reacts with S895-phosphorylated
VprBP. The specificity of the purified antibody was verified by dot
blot and peptide competition assays using the unmodified and
phosphorylated peptides (Fig. 8F). In addition, the affinity-
FIG 7 Stimulation of p53 transcription and apoptosis by VprBP knockdown. (A) Western blot analysis of normal and cancer cells. Exponentially growing
normal (Urotsa, MLC, and MCF10-2A) and cancer (LD611, LNCaP, and MCF7) cells were subjected to Western blot analysis using anti-VprBP, anti-p53, and
anti-HDAC1 antibodies. Actin served as a control for equal protein loading. (B) RNAi-mediated depletion of VprBP. LD611, LNCaP, and MCF7 cells were
transfected with a control siRNA (lanes 1, 3, and 5) or a siRNA directed against VprBP (lanes 2, 4, and 6) for 72 h and analyzed by Western blotting using the
indicated antibodies. All analyses were performed in parallel for each of the three cell lines. (C) Activation of the p21 and Noxa genes by VprBP depletion. Cells
were first transfected with siRNA targeting VprBP or an irrelevant control (NC) as in panel B and treated with or without etoposide (100 M) for 24 h.
Transcription levels of the p21 and Noxa genes were analyzed by qRT-PCR. (D) Upregulation of DNA damage-induced apoptosis by VprBP depletion. After
transfected with either a control siRNA or a VprBP siRNA, cells were DMSO treated or etoposide treated as for panel C. The apoptotic status of cells was analyzed
by assessing annexin V-FITC fluorescent intensity. Averages and standard deviations are shown for data from three independent experiments.
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purified antibody reacted strongly with phosphorylated wild-type
VprBP but not with unmodified wild-type VprBP and phosphor-
ylated S895-mutated VprBP (Fig. 8G).
Phosphorylation inhibits transrepression activity of VprBP.
We next assessed the contribution of S895 phosphorylation to the
H3 tail binding and transrepressive activities of VprBP. As deter-
mined by Western blotting, etoposide-induced DNA damage re-
sulted in a rapid phosphorylation of VprBP at S895, but no change
in the cellular concentration of VprBP was observed (Fig. 9A).
Immunofluorescence analysis also indicated a considerable in-
crease in VprBP phosphorylation in cells that had been treated
with etoposide (Fig. 9B). To check the effect of VprBP phosphor-
ylation on VprBP-H3 tail interaction, the glutathione-Sepharose-
bound GST-H3 tail was incubated with unphosphorylated or
phosphorylated Flag-VprBP, and the bead-bound VprBP fraction
was analyzed by Western blotting with anti-Flag antibody (Fig.
9C). The interaction between the H3 tail and wild-type VprBP was
reduced by 80% following the phosphorylation of VprBP (lanes
FIG 8 Phosphorylation of VprBP by DNA-PK. (A) Western blot analysis of VprBP and p53 after DNA damage. U2OS cells were DMSO treated or etoposide
treated for 12 h, and cell lysates were subjected to Western blotting using the indicated antibodies. (B) Posttranslational modification of VprBP. In vitro
modification assays were performed with a panel of kinases, acetyltransferases, and methyltransferases using VprBP (lanes 1 to 9) or H2AX histone octamer (lanes
10 to 18) as a substrate. The reactions were analyzed by SDS-PAGE and autoradiography as described in Materials and Methods. (C) Determination of the
phosphorylation domain of VprBP. The indicated domains of VprBP were generated in E. coli and subjected to in vitro kinase assays using DNA-PK and
[-32P]ATP. (D) Mapping VprBP phosphorylation sites by mass spectrometry. A representative MS/MS spectrum of the major phosphopeptide sequence, which
identified phosphorylation at S895, is shown. The theoretical fragment mass of phosphoserine is highlighted. (E) Mutational analysis of the identified VprBP
phosphorylation site. An in vitro kinase assay was performed using DNA-PK and [-32P]ATP as for panel C but with VprBP 751–909 mutated at S895. (F)
Generation of a phospho-S895-specific antibody. Dot blotting of unmodified (U) and phosphorylated (P) peptides was performed in the presence of either the
unmodified or the phosphorylated peptides during the antibody binding step. (G) Specificity of phospho-S895 antibody. Wild-type and mutant VprBP 751–909
proteins were phosphorylated by DNA-PK and cold ATP and analyzed by Western blot analysis using the phospho-S895 antibody.
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FIG 9 Alleviation of VprBP-induced repression by phosphorylation. (A) Western blotting of S895 phosphorylation after DNA damage. Cell extracts were
prepared 8 h after etoposide treatment of U2OS cells and analyzed by Western blot analysis using VprBP and phospho-S895 VprBP antibodies. (B) Immuno-
staining of S895 phosphorylation after DNA damage. U2OS cells were treated with etoposide as for panel A and stained with phospho-S895 VprBP antibody.
Increased staining for S895 phosphorylation is evident after etoposide-induced DNA damage. (C) Impaired interaction of VprBP with H3 tail upon phosphor-
ylation. In vitro binding experiments using immobilized H3 tails were performed with phosphorylated or unphosphorylated wild type (WT) (lanes 1 to 3) and
S895-mutated (lanes 4 to 6) VprBP. VprBP binding to H3 tails was determined by Western blotting using anti-Flag antibody. (D) Stimulatory effect of VprBP
phosphorylation on transcription. Transcription reactions were identical to those in Fig. 3C, but wild-type and mutant VprBP 751–1507 fragments were
premodified by DNA-PK. (E) Differential effects of wild-type and S895-mutated VprBP on p21 and Noxa transcription. U2OS cells were transfected with
Myc-tagged versions of wild-type and S895-mutated VprBP for 48 h and treated with etoposide for additional 12 h. p21 and Noxa mRNA levels were analyzed
by using qRT-PCR. (F) Phosphorylation-dependent dissociation of VprBP from the promoter. U2OS cells were transfected with wild-type and S895-mutated
VprBP as for panel E. ChIP assays after etoposide treatment were essentially as described for Fig. 5B. (G) Model for VprBP inhibition of p53-mediated
transcription. Under unstressed conditions, VprBP is brought to p53-responsive promoters by p53 and acts as a molecular rheostat to block transcription
initiation by binding to unacetylated H3 tails. For the most efficient repression, VprBP cooperates with HDAC1 to remove and block H3 acetylation. Upon DNA
damage, the majority of VprBP is phosphorylated by DNA-PK and dissociated from the promoter nucleosomes. HAT then acetylates H3 tails and establishes an
active promoter environment for p53 to achieve the most efficient transcription of proapoptotic genes. In this way, cells would achieve more accurate and efficient
regulation of the p53 transcriptional network. See Discussion for further details.
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2 and 3), but there was no disruption of H3 tail-mutant VprBP
interaction after the phosphorylation reaction (lanes 5 and 6).
To analyze the functional effect of VprBP phosphorylation,
transcription assays were performed as in Fig. 3C, except that
DNA-PK was added to phosphorylate VprBP in the reaction. As
shown in Fig. 9D, DNA-PK antagonized the repressive action of
VprBP and produced a distinct enhancement of p53-dependent,
p300-mediated transcription from p53ML-601 nucleosome ar-
rays (lanes 5 and 6). On the contrary, the ability of DNA-PK to
enhance the nucleosome array transcription was significantly
compromised when wild type VprBP was replaced by S895-
mutated VprBP (lanes 7 and 8). These results, together with the
results from the binding assays (Fig. 9C), strongly suggest that the
phosphorylation of S895 is the major cause of impaired repressive
action of VprBP. Additional support for the regulatory role of
S895 phosphorylation in VprBP activity came from transfection
experiments in which wild-type or mutant VprBP was expressed
in U2OS cells and the impact of DNA damage on p53 transactiva-
tion was measured by qRT-PCR. The data shown in Fig. 9E indi-
cate that blocking DNA damage-induced S895 phosphorylation
by mutation has a positive influence on VprBP-induced repres-
sion of p53 transactivation.
In view of the antagonizing effect of phosphorylation on
VprBP-H3 tail interaction and VprBP-induced repression, ChIP
analysis was performed with U2OS cells ectopically expressing
wild-type and S895-mutated forms of VprBP. As expected, we
observed a specific localization of wild-type VprBP at the p21 and
Noxa promoters in the absence of DNA damage and its dissocia-
tion following etoposide-induced DNA damage (Fig. 9F, VprBP,
Myc-VprBP WT). In correlation with the release of VprBP, the
rapid accumulation of H3 acetylation at the promoter regions was
detected after DNA damage (AcH3, Myc-VprBP WT). Remark-
ably, however, parallel ChIP analyses with mutant VprBP showed
no apparent change in VprBP occupancy (VprBP, Myc-VprBP
S895A) and a slight increase in H3 acetylation around the pro-
moter regions in response to DNA damage (AcH3, Myc-VprBP
S895A). We therefore conclude that VprBP phosphorylation at
S895 occurs upon DNA damage and that this phosphorylation is
critical for DNA damage-induced activation of p53 response
genes.
DISCUSSION
Although VprBP was originally implicated in HIV-1 replication
and pathogenesis based on its interaction with the HIV-1 protein
Vpr, a recent study revealed that VprBP knockdown increases the
level of the endogenous p21 protein under normal growth condi-
tions (11). However, it was unknown whether transcription is the
primary target for VprBP and if so how VprBP modulates tran-
scription of p53 target genes, such as the p21 gene. In this study,
we explored the hypothesis that VprBP could generate a repressive
environment at p53 target genes and antagonize DNA damage-
induced apoptosis. Taking advantage of our well-defined in vitro
transcription system, we demonstrated that VprBP can act as a
negative regulator of p53-mediated chromatin transcription when
added prior to p300 HAT. It is worth noting that the use of recom-
binant histones for chromatin assembly allowed us to exclude the
effect of any prior modifications that could influence the repres-
sive action of VprBP. In striking contrast, the repressive properties
of VprBP cannot be recapitulated by the addition of p300 HAT
prior to VprBP or the simultaneous addition of VprBP and p300
HAT, pointing to a mechanism that is dependent upon the unac-
etylated state of nucleosomes. Consistent with this notion, we
found that VprBP specifically interacts with unacetylated H3 tails
protruding from inactive nucleosomes. Thus, apart from our
demonstration of VprBP as a new repressor in regulating p53
transactivation potential, these results point to a direct link be-
tween the unacetylated state of H3 tails and the repressive prop-
erty of VprBP.
Our studies also show that the LisH motif of VprBP plays a
dominant role in repressing p53-mediated chromatin transcrip-
tion. These results can be explained by an intrinsic ability of the
LisH motif to recognize unmodified H3 tails. In fact, our interac-
tion studies confirmed the requirement of the LisH motif for the
interaction between VprBP and unmodified H3 tails. Notably, our
results contrast with those of a recent study showing that the LisH
motif in transducin beta-like protein 1 and its receptor (TBL1 and
TBLR1) binds to the hypoacetylated H4 tail for chromatin target-
ing by the nuclear receptor corepressor complex (4). This may
reflect a low degree of sequence homology (only 30%) in their
LisH motifs, which could discriminate between related but dis-
tinct regions of H3 and H4 tails. Thus, whether LisH motifs in
different proteins recognize different histone tails is an intriguing
question that needs to be addressed in future studies.
In accord with our in vitro studies, RNAi-complemented ChIP
analyses demonstrate that VprBP is necessary for the maintenance
of repressed states of p53 target genes under normal unstressed
conditions. Importantly, the ability of VprBP in establishing this
repressed environment relies on its initial recruitment by p53 as
well as its ability to recognize unmodified H3 tails. One important
aspect revealed in this regard is that HDAC1 acts as a gatekeeper to
prevent H3 acetylation at the p21 and Noxa promoters, support-
ing its role in stimulating stable action of VprBP at the promoter
regions. Because VprBP is required for initial recruitment of
HDAC1 to the promoters, functional significance of the VprBP-
HDAC1 interaction should also be emphasized. In further sup-
port of the interplay between VprBP and HDAC1 in constraining
p53 transcription, DNA damage-induced activation of p53 target
genes was accompanied by dissociations of VprBP and HDAC1
and concomitant accumulation of H3 acetylation. The critical role
of VprBP in the p53 signaling pathway is further underscored by
the finding that a high level of VprBP is detected in three human
cancer cell lines, which reinforces our hypothesis that misregula-
tion of VprBP expression maintains the repressive state of p53
target genes and interferes with the apoptotic capability of cells. In
agreement with this hypothesis, VprBP knockdown in these can-
cer cells results in an apparent stimulation of p53 transcription
and apoptotic cell death in response to etoposide treatment. These
data constitute a powerful argument that overexpression of
VprBP in cancer cells antagonizes transcription of p53 target
genes encoding proapoptotic factors.
Another intriguing observation from our study is that VprBP is
phosphorylated by DNA-PK at S895, and mutation of this serine
residue greatly diminishes the ability of VprBP to repress p53-
dependent chromatin transcription. The finding that DNA-PK-
mediated phosphorylation of VprBP leads to the dissociation of
VprBP from promoter nucleosomes and the reactivation of p53
target genes also points to the functional importance of this mod-
ification in limiting the repressive action of VprBP upon DNA
damage (Fig. 9F). Because S895 is located immediately C-terminal
to the LisH motif of VprBP, phosphorylation may affect the struc-
Repression of p53 Transcription by VprBP
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tural integrity of the LisH motif and therefore alter its affinity for
H3 tails. Mechanistically, it is also reasonable to speculate that
VprBP phosphorylation might antagonize the initial localization
of VprBP at the promoter. In this respect, it will be interesting to
distinguish the effects of S895 phosphorylation on VprBP disso-
ciation versus VprBP association at the promoter nucleosomes.
There are also other possible aspects of the regulation of VprBP
activity by S895 phosphorylation. For instance, we do not yet
know the consequence of VprBP phosphorylation for the p53-
VprBP interaction, which is critical for the promoter-targeted re-
cruitment of VprBP. Such early regulation of VprBP would ben-
efit the fine-tuning of p53 transcriptional responses. Therefore,
further characterization of physiological and oncogenic activities
of VprBP has broad implications for the repertoire and complex-
ity of the regulatory mechanisms underlying p53 signaling path-
ways.
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